| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a799d17d5f808bee28dc9a15345a54f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 |
| filingDate |
2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9334d6d396c199f51b2a83b5b0ae25b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b332e1572f95a464ec66b586471d3529
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b3eb3561524efa2868aa46dba62783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c53a22ecc9091c8db984a30e3bc9926 |
| publicationDate |
2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-031319-B1 |
| titleOfInvention |
ACTIVE METABOLIT DIMEZILATMONHYDRAT 1 - [(2-BROMPHENYL) SULPHONYL] -5-METOXY-3 - [(4-METHYL-1-PIPERASININYL) METHYL] -1H-INDOLA and DIMEZYLETDIHDRETT RETRATTRAHRETRETRITRETRATRETR. |
| abstract |
The invention relates to the active metabolite of dimesylate monohydrate 1 - [(2-bromophenyl) sulfonyl] -5-methoxy-3 - [(4-methyl-1-piperazinyl) methyl] -1H-indole, having the following structure: The invention also relates to the dimesylate dihydrate salt Formula (I) having the following structure: The compounds of the formula (I) and the formula (II) are useful in treating various diseases that are associated with the 5-HT receptor antagonist. |
| priorityDate |
2014-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |